(Q28262548)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6292222&resulttype=core&format=json

13 May 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6292222&resulttype=core&format=json

13 May 2020

3

Steven A Rosenberg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6292222&resulttype=core&format=json

13 May 2020

author name string

Mark E Dudley

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6292222&resulttype=core&format=json

Nature Reviews Immunology

13 May 2020

language of work or name

English

0 references

publication date

22 March 2012

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6292222&resulttype=core&format=json

13 May 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6292222&resulttype=core&format=json

13 May 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6292222&resulttype=core&format=json

13 May 2020

page(s)

269-281

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6292222&resulttype=core&format=json

Intravital imaging reveals distinct dynamics for natural killer and CD8(+) T cells during tumor regression

13 May 2020

cites work

1 reference

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

31 March 2020

1 reference

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

31 March 2020

1 reference

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

31 March 2020

1 reference

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

31 March 2020

1 reference

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

31 March 2020

1 reference

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

31 March 2020

1 reference

Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients

31 March 2020

1 reference

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

31 March 2020

1 reference

Antigen choice in adoptive T-cell therapy of cancer

31 March 2020

1 reference

Identification of human cancers deficient in antigen processing

31 March 2020

1 reference

Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy

31 March 2020

1 reference

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

31 March 2020

1 reference

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

31 March 2020

1 reference

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

31 March 2020

1 reference

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

31 March 2020

1 reference

Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen

31 March 2020

1 reference

gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand

31 March 2020

1 reference

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

31 March 2020

1 reference

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

31 March 2020

1 reference

Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity

31 March 2020

1 reference

Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma

31 March 2020

1 reference

Analysis of the genome to personalize therapy for melanoma

31 March 2020

1 reference

Delving into somatic variation in sporadic melanoma

31 March 2020

1 reference

Molecular aspects of tanning

31 March 2020

1 reference

A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes

31 March 2020

1 reference

Adoptive T cell therapy of cancer

31 March 2020

1 reference

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia

31 March 2020

1 reference

Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer

31 March 2020

1 reference

A novel retinoblastoma therapy from genomic and epigenetic analyses

31 March 2020

1 reference

Genome-wide analysis of cancer/testis gene expression

31 March 2020

1 reference

CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens

31 March 2020

1 reference

A decade of exploring the cancer epigenome - biological and translational implications

31 March 2020

1 reference

De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.

31 March 2020

1 reference

Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression

31 March 2020

1 reference

Cancer/testis antigens, gametogenesis and cancer

31 March 2020

1 reference

A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.

31 March 2020

1 reference

Leukocyte composition of human breast cancer

31 March 2020

1 reference

Targeting stroma to treat cancers

31 March 2020

1 reference

Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha

31 March 2020

1 reference

Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice

31 March 2020

1 reference

Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer

31 March 2020

1 reference

Targeting the tumour vasculature: insights from physiological angiogenesis

31 March 2020

1 reference

Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes

31 March 2020

1 reference

Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.

31 March 2020

1 reference

Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways

31 March 2020

1 reference

Cancer therapy using a self-replicating RNA vaccine

31 March 2020

1 reference

Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.

31 March 2020

1 reference

Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma

31 March 2020

1 reference

Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors

31 March 2020

1 reference

Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen

31 March 2020

1 reference

Recent advances in therapeutic cancer vaccines

31 March 2020

1 reference

Cancer immunotherapy: moving beyond current vaccines

31 March 2020

1 reference

Therapeutic cancer vaccines: are we there yet?

31 March 2020

1 reference

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

31 March 2020

1 reference

Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy

31 March 2020

1 reference

Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients

31 March 2020

1 reference

Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice

31 March 2020

1 reference

Natural selection of tumor variants in the generation of "tumor escape" phenotypes

31 March 2020

1 reference

Cancer immunology--analysis of host and tumor factors for personalized medicine

31 March 2020

1 reference

Exploring the genomes of cancer cells: progress and promise

31 March 2020

1 reference

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

31 March 2020

1 reference

Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells

31 March 2020

1 reference

Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.

31 March 2020

1 reference

T-cell receptor gene therapy of established tumors in a murine melanoma model

31 March 2020

1 reference

Cancer regression in patients after transfer of genetically engineered lymphocytes

31 March 2020

1 reference

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

31 March 2020

1 reference

Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor

31 March 2020

1 reference

The promise and potential pitfalls of chimeric antigen receptors

31 March 2020

1 reference

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

31 March 2020

1 reference

Bispecific antibodies engage T cells for antitumor immunotherapy

31 March 2020

1 reference

Genetically modulating T-cell function to target cancer.

31 March 2020

1 reference

A human memory T cell subset with stem cell-like properties

31 March 2020

1 reference

T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection

31 March 2020

1 reference

Bcl-2 overexpression enhances tumor-specific T-cell survival

31 March 2020

1 reference

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

31 March 2020

1 reference

IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.

31 March 2020

1 reference

Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts

31 March 2020

1 reference

Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses

31 March 2020

1 reference

Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy

31 March 2020

1 reference

Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells

31 March 2020

1 reference

Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells.

31 March 2020

1 reference

Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity

31 March 2020

1 reference

Prospects and limitations of T cell receptor gene therapy

31 March 2020

1 reference

Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial

31 March 2020

1 reference

Inducible apoptosis as a safety switch for adoptive cell therapy

31 March 2020

1 reference

Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells

31 March 2020

1 reference

Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells

31 March 2020

1 reference

Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells

31 March 2020

1 reference

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

31 March 2020

1 reference

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

31 March 2020

1 reference

Coordinated regulation of myeloid cells by tumours

31 March 2020

1 reference

Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection

31 March 2020

1 reference

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

31 March 2020

1 reference

Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling.

31 March 2020

1 reference

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

31 March 2020

1 reference

Regulatory T cells selectively control CD8+ T cell effector pool size via IL-2 restriction

31 March 2020

1 reference

CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.

31 March 2020

1 reference

The yin and yang of interleukin-2-mediated immunotherapy

31 March 2020

1 reference

Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells

31 March 2020

1 reference

Adoptive immunotherapy for cancer: building on success

31 March 2020

1 reference

31 March 2020

1 reference

CD8+ T-cell memory in tumor immunology and immunotherapy

31 March 2020

1 reference

Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function

31 March 2020

1 reference

Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.

31 March 2020

1 reference

Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.

31 March 2020

1 reference

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells

31 March 2020

1 reference

IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells

31 March 2020

1 reference

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

31 March 2020

1 reference

Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice

31 March 2020

1 reference

Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype

31 March 2020

1 reference

Host-reactive CD8+ memory stem cells in graft-versus-host disease

31 March 2020

1 reference

Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells

31 March 2020

1 reference

Harnessing the biology of IL-7 for therapeutic application

31 March 2020

1 reference

The B7 and CD28 receptor families

31 March 2020

1 reference

Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells

31 March 2020

1 reference

IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy

31 March 2020

1 reference

Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.

31 March 2020

1 reference

Wnt/beta-catenin signaling in T-cell immunity and cancer immunotherapy

31 March 2020

1 reference

Pharmacologic induction of CD8+ T cell memory: better living through chemistry

31 March 2020

1 reference

The role of CD4+ T cell responses in antitumor immunity

31 March 2020

1 reference

Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.

31 March 2020

1 reference

Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

31 March 2020

1 reference

CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma

31 March 2020

1 reference

Primary antitumor immune response mediated by CD4+ T cells

31 March 2020

1 reference

T helper 17 cells promote cytotoxic T cell activation in tumor immunity

31 March 2020

1 reference

Tumor-specific Th17-polarized cells eradicate large established melanoma

31 March 2020

1 reference

Th17 cells are long lived and retain a stem cell-like molecular signature

31 March 2020

1 reference

Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.

31 March 2020

1 reference

Adoptive therapy using antigen-specific T-cell clones

31 March 2020

1 reference

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1

31 March 2020

1 reference

Helper T cell diversity and plasticity

31 March 2020

1 reference

The critical role of Th1-dominant immunity in tumor immunology.

31 March 2020

1 reference

Adoptive immunotherapy of cancer using CD4(+) T cells

31 March 2020

1 reference

T(H)17 cells in tumour immunity and immunotherapy.

31 March 2020

1 reference

Does IL-17 promote tumor growth?

31 March 2020

1 reference

Type 17 CD8+ T cells display enhanced antitumor immunity.

31 March 2020

1 reference

Tc17 CD8 T cells: functional plasticity and subset diversity.

31 March 2020

1 reference

Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers.

31 March 2020

1 reference

Combination of targeted therapy and immunotherapy in melanoma

31 March 2020

1 reference

Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination.

31 March 2020

1 reference

Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

31 March 2020

1 reference

Can antitumor immunity help to explain "oncogene addiction"?

31 March 2020

1 reference

CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation

31 March 2020

1 reference

The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells

31 March 2020

1 reference

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

31 March 2020

1 reference

Expression of tumour-specific antigens underlies cancer immunoediting

31 March 2020

1 reference

Induction of antigen-specific T cell anergy: An early event in the course of tumor progression

31 March 2020

1 reference

The central role of CD4(+) T cells in the antitumor immune response

31 March 2020

1 reference

Human TH17 cells are long-lived effector memory cells.

31 March 2020

1 reference

Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens

31 March 2020

1 reference

12 December 2020

Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.

1 reference

12 December 2020

Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other".

1 reference

12 December 2020

Clinical experience with gene therapy and bispecific antibodies for T cell-based therapy of cancer

1 reference

12 December 2020

Passive Immunotherapy of Cancer in Animals and Man

1 reference

12 December 2020

Immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice.

1 reference

12 December 2020

Specificity of adoptive chemoimmunotherapy of established syngeneic tumors

1 reference

12 December 2020

Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen

1 reference

12 December 2020

IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases

1 reference

12 December 2020

Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen

1 reference

12 December 2020

Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.

1 reference

12 December 2020

IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.

1 reference

12 December 2020

Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A

1 reference

12 December 2020

Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRI3191

2 references

Consolidated OpenCitations Corpus – April 2017

42260

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6292222&resulttype=core&format=json

13 May 2020

42260

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6292222&resulttype=core&format=json

13 May 2020

PubMed publication ID

22437939

2 references

Consolidated OpenCitations Corpus – April 2017

42260

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6292222&resulttype=core&format=json